SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan® Assay
Brings differentiated miniaturization technology, scientific and engineering expertise, and enhanced ease-of-use capabilities to SomaLogic's platform while expanding footprint to San Diego, CA BOULDER, Colo. and SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today announced it entered into an agreement to acquire Palamedrix, Inc., an innovator in DNA nanotechnology. Palamedrix provides deep scientific and engineering expertise, miniaturization technology and enhanced ease-of-use capabilities that SomaLogic intends to leverage as it develops the next generation of the SomaScan® Assay. The acquisition brings two leadin
